Wealth Alliance Advisory Group LLC Has $3.54 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Wealth Alliance Advisory Group LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 1.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,582 shares of the company’s stock after purchasing an additional 55 shares during the quarter. Eli Lilly and Company comprises 0.7% of Wealth Alliance Advisory Group LLC’s holdings, making the stock its 28th largest holding. Wealth Alliance Advisory Group LLC’s holdings in Eli Lilly and Company were worth $3,537,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Moss Adams Wealth Advisors LLC grew its position in shares of Eli Lilly and Company by 1.0% during the 4th quarter. Moss Adams Wealth Advisors LLC now owns 2,534 shares of the company’s stock worth $1,956,000 after buying an additional 25 shares during the period. Monarch Capital Management Inc. boosted its stake in Eli Lilly and Company by 17.7% during the fourth quarter. Monarch Capital Management Inc. now owns 1,368 shares of the company’s stock worth $1,056,000 after acquiring an additional 206 shares in the last quarter. Astoria Portfolio Advisors LLC. grew its holdings in Eli Lilly and Company by 4.2% in the fourth quarter. Astoria Portfolio Advisors LLC. now owns 1,048 shares of the company’s stock worth $781,000 after purchasing an additional 42 shares during the period. Kera Capital Partners Inc. bought a new stake in Eli Lilly and Company in the fourth quarter valued at $231,000. Finally, Raub Brock Capital Management LP raised its holdings in shares of Eli Lilly and Company by 0.5% during the fourth quarter. Raub Brock Capital Management LP now owns 24,010 shares of the company’s stock valued at $18,536,000 after purchasing an additional 131 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $726.24 on Monday. The business’s fifty day simple moving average is $781.14 and its 200 day simple moving average is $854.35. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 12 month low of $612.70 and a 12 month high of $972.53. The firm has a market capitalization of $689.43 billion, a P/E ratio of 78.51, a price-to-earnings-growth ratio of 1.66 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.10 earnings per share. As a group, analysts anticipate that Eli Lilly and Company will post 13.14 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.83%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. Eli Lilly and Company’s payout ratio is presently 64.86%.

Eli Lilly and Company announced that its Board of Directors has initiated a share buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 2% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its stock is undervalued.

Analysts Set New Price Targets

Several analysts have recently commented on LLY shares. Bank of America restated a “buy” rating and issued a $997.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Wolfe Research assumed coverage on Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective for the company. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Truist Financial lifted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. Finally, StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, January 1st. Four research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,002.22.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.